Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

A Phase 2, Open-label, Controlled, Multi-center Study to Evaluate Meningococcal ACWY Antibody Response in Children Aged 40 and 60 Months Who Have Previously Received Novartis MenACWY Conjugate Vaccine as Infants

The purpose of this study is to evaluate how well the immuno response against meningococcal serogroups A, C, W and Y lasts in children who were vaccinated with MenACWY as infants.

Inclusion Criteria:

• Follow-on, healthy 40, 60 months old participants who have completed the V59P5 study and are in good health
• Control subjects: healthy 60 months old who had received a complete MenC immunization course

Exclusion Criteria:

• Subjects with any serious, acute or chronic progressive disease